3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
12
Lung Neoplasms
8
Neoplasm Metastasis
6
Breast Neoplasms
6
Thyroid Neoplasms
4
Prostatic Neoplasms
4
Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Urinary Bladder Neoplasms
2
Pleural Effusion
2
Ovarian Neoplasms
2
Kidney Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Medullary
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thyroid cancer, medullary
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Relapsed Pediatric Solid Tumor
1
Recurrence
1
Rectal Neoplasms
1
Precancerous Conditions
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Non-small Cell Lung Cancer Metastatic
1
Interventions
Pemetrexed
4
pembrolizumab
3
Ramucirumab
2
Gemcitabine
2
Carboplatin
2
vistusertib
1
vandetanib
1
tusamitamab ravtansine
1
telomerase reverse transcriptase p572Y, human
1
sintilimab
1
olaparib
1
necitumumab
1
icotinib
1
durvalumab
1
dacomitinib
1
capivasertib
1
Vinorelbine
1
LY3023414
1
Injections
1
Immune Checkpoint Inhibitors
1
Erlotinib Hydrochloride
1
Drug Therapy
1
Docetaxel
1
Cisplatin
1
Bevacizumab
1
AZD4547
1
AZD 8931
1
AZD 6244
1
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Non-small Cell Lung Cancer Metastatic
×
vandetanib
×
Clear all
NCT02117167
2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2
Completed
999 enrolled